[Bronchiolitis--we don't know how to treat--we can prevent].
Broncholitis in infant is most commonly results from viral infection, typically RS virus will be responsible. Treatment is difficult due to limited efficacy of available methods of causal and symptomatic therapies. Therefore it is specially important to seek preventive measures. This is crucial in case of preterm infants, infants with broncho-pulmonary dysplasia, cystic fibrosis, hemodynamically significant congenital heart defects and immunodeficiencies who are likely to undergo a severe course of the disease. In the above mentioned cases the effects of passive immunotherapy of prophylaxis with initially intravenous anti RSV-immunoglobulin G, then intramuscular monoclonal antibody palivizumab have been assessed. Palivizumab is currently recommended by American Academy of Pediatrics for RSV infection prophylaxis with children at risk like infants with broncho-pulmonary dysplasia, preterm infants depending on gestational age and infant age in infection season as well as infants with hemodynamically significant congenital heart defects. So far there is no possibility to prevent infection within the whole population.